FDA rejects Merck's insomnia drug
(Reuters) - Merck & Co Inc said the U.S. Food and Drug Administration rejected the company's experimental insomnia drug, citing safety issues.
In a complete response letter to the company, the FDA said the safety data of the drug do not support approval, and advised that lower doses of the medicine should be made available before an approval.
The efficacy of the drug, suvorexant, was established at doses of 10 mg to 40 mg in adults, the FDA said, adding that 10 mg should be the starting dose for most patients.
(Reporting by Esha Dey in Bangalore)
- IPhone emerges from 'bygone era', reviewers hail bigger handset
- On eve of secession vote, UK's fate hangs on a divided Scotland |
- Fed renews zero rate pledge, but hints at steeper rate hike path
- Boeing, SpaceX win contracts to build 'space taxis' for NASA
- Islamic State campaign tests Obama's commitment to Mideast allies
Major U.S. poultry firms are administering antibiotics to their flocks far more pervasively than regulators realize, posing a potential risk to human health. Full Article